Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267208 | 0.88 | ALDH1A1 (0.54) | MAPK1KDM4EKMT2ATSHRALDH1A1 | |
| SCHEMBL235046 | 0.87 | TSHR (0.60) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL11225504 | 0.86 | CYP4F2 (0.67) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL5248889 | 0.86 | MAPK1 (0.54) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL19971601 | 0.84 | MAPK1 (0.52) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL3303821 | 0.84 | CA1 (0.70) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL3303156 | 0.83 | MAPK1 (0.55) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL31268668 | 0.83 | MAPK1 (0.51) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL29952924 | 0.83 | MAPK1 (0.51) | MAPK1KDM4EKMT2ATSHRALOX15 | |
| SCHEMBL1187950 | 0.83 | ALDH1A1 (0.60) | MAPK1KDM4EKMT2ATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023048034-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING ETHYNYL GROUP | 東レ・ファインケミカル株式会社 | 2023-03-30 | — | — | WO | disclosed |
| WO-2019196731-A1 | SUBSTITUTED PYRAZOLYL PYRAZOLE SULFONYLUREA COMPOUND OR PESTICIDE ACCEPTABLE SALT OR COMPOSITION THEREOF AND USE THEREOF | 海利尔药业集团股份有限公司 | 2019-10-17 | — | — | WO | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2012-04-05 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110681-B2 | Compounds for the treatment of spinal muscular atrophy and other uses | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2007109211-A2 | 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-4816591-A | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives | AMERICAN HOECHST CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| US-4585788-A | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives | AMERICAN HOECHST CORPORATION (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0093488-A2 | Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
| US-4082850-A | TOPICAL APPLICATION OF A 6,11-DIHYDROBENZ(B,E)OXEPIN-ALKANOIC ACID OR DERIVATIVES THEREOF | AMERICAN HOECHST CORPORATION (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | MAPK1 43/4885KDM4E 1229/4885KMT2A 1487/4885 |
| US-20120083495-A1 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, RNMT, CPT1B | MAPK1 4151/4885KDM4E 2775/4885KMT2A 828/4885 |
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | MAPK1 1585/4885KDM4E 4291/4885KMT2A 3313/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | MAPK1 1585/4885KDM4E 4291/4885KMT2A 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.